Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
522 studies found for:    "Lupus Erythematosus, Systemic"
Show Display Options
Rank Status Study
21 Enrolling by invitation An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults
Condition: Lupus Erythematosus, Systemic
Intervention: Biological: MEDI-546
22 Suspended Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
Condition: Systemic Lupus Erythematosus
Interventions: Drug: N-acetylcysteine;   Drug: Placebo
23 Recruiting Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
Condition: Systemic Lupus Erythematosus
Interventions: Drug: MT-1303 Low dose;   Drug: MT-1303 High dose
24 Terminated
Has Results
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Other: Placebo;   Biological: MEDI-570 0.03 MG;   Biological: MEDI-570 0.1 MG;   Biological: MEDI-570 0.3 MG;   Biological: MEDI-570 1 MG
25 Active, not recruiting Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Atacicept 75 mg;   Drug: Atacicept 150 mg
26 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
27 Completed Omega 3 Fatty Acids and Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Dietary Supplement: Hiomega-3 supplement of Naturalis® company -
28 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
29 Active, not recruiting Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: ACT-334441;   Drug: Placebo
30 Recruiting Walk With Ease Program For Patients With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Other: "Walk With Ease"
31 Completed Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: cytarabine
32 Terminated Physical Therapy for Systemic Lupus Erythematosus (SLE)
Conditions: Lupus Erythematosus, Systemic;   SLE
Intervention: Behavioral: Physical Therapy or Relaxation Therapy
33 Unknown  Effectiveness Study of Psychotherapy in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Behavioral: Psychotherapy
34 Recruiting A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Ustekinumab IV;   Drug: Placebo Infusion;   Drug: Placebo SC;   Drug: Ustekinumab SC;   Other: Concomitant Medication
35 Completed The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS
Condition: Systemic Lupus Erythematosus
Intervention: Drug: versus hydroxychloroquine
36 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
37 Recruiting Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
38 Not yet recruiting Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
Conditions: Lupus Erythematosus, Systemic;   Musculoskeletal Pain
Interventions: Device: Vagus nerve stimulation;   Device: Sham vagus nerve stimulation
39 Completed Abnormalities of B Lymphocytes During Systemic Lupus
Condition: Systemic Lupus Erythematosus
Intervention: Procedure: Blood samples
40 Terminated Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
Condition: Systemic Lupus
Intervention: Drug: Arsenic trioxide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.